CBP Issues Warning on Biological Material Import Violations in Clinical Research
核心洞察
US Customs and Border Protection reports a concerning rise in non-compliant biological material imports, with over 107,510 pounds of regulated drugs seized last year.
Multiple agency approvals, including FDA, USDA (搜索), and CDC (搜索) permits, are required for importing biological research materials, with many researchers failing to meet all regulatory requirements.
Common violations involve transportation of plasmids, preserved animal tissue, and primate materials, posing potential biological security threats even when intended for legitimate research purposes.
The U.S. Customs and Border Protection (搜索) (CBP) has raised significant concerns about the improper transportation of biological materials into the United States, highlighting increasing risks to national biosecurity. Speaking at the Outsourcing in Clinical Trials Conference in New England, CBP officials detailed the growing challenges in managing research material imports.
Rising Non-Compliance in Biological Imports
Sean Smith, CBP's biological threat exclusion coordinator, revealed alarming statistics from the previous year's enforcement efforts. The agency intercepted 549,238 pounds of drugs, with 107,510 pounds comprising regulated substances beyond narcotics. "We are seeing more and more non-compliant biological materials coming in," Smith emphasized during his presentation.
Common Violations and Materials
Baljeet Kaur, CBP's agriculture operations manager, identified several problematic categories of imported materials:
- Plasmids
- Preserved animal tissue
- Cryo-containers
- Primate materials
While many of these materials serve legitimate research purposes, improper documentation and transportation protocols force CBP to treat them as potential biological threats.
Multi-Agency Regulatory Requirements
A critical issue highlighted during the conference is the widespread misunderstanding of multi-agency approval requirements. Smith explained that FDA approval alone does not guarantee import clearance. "Just because the US Food and Drug Administration has approved something it does not mean it's approved to come into the country," he stated, emphasizing that many products require clearance from multiple regulatory bodies.
Proper Import Procedures
To ensure compliant importation of biological materials, researchers must:
- Obtain necessary permits from the USDA and/or CDC
- Submit declarations for primate, fish, and wildlife products before leaving the country
- Comply with Department of Transportation requirements
- Ensure proper documentation for all regulated materials
Impact on Clinical Research
The strict enforcement of these regulations directly affects clinical research operations. Personal medication transport is limited to individual use only, with broader research material transportation requiring comprehensive regulatory compliance. Smith emphasized that following proper procedures ensures both the safe transport of necessary materials and the protection of U.S. borders.